Project SABRINA (Sepsis Alert Biomarkers Resolved In a Novel Assay)
Lead Participant:
MOLOGIC LTD.
Abstract
A simple, easy to use, rapid, inexpensive, effective, point of care (POC) immunodiagnostic system for early confirmation of sepsis in at-risk patients is to be developed and validated. The biomarkers will include IL-6, C-reactive protein and soluble ICAM-1. These known biomarkers will be integrated via a new algorithm with other physical/clinical indicators, and refined using a unique bank of "sepsis-risk" patient samples and controls held within the consortium, before final clinical validation. Strong pilot data gained with the markers and the sample bank gives confidence in their utility and relevance. As well as universal threshold values for each analyte, the algorithm may also be based on sequential personalised values, determined using a low-cost reader (developed outside of the proposed project) to give more accurate readings. The assay is to be based on a simple multiplexed immunoassay platform already being developed by Mologic in a parallel TSB project due to finish in April 2012.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
MOLOGIC LTD. | £590,157 | £ 241,492 |
  | ||
Participant |
||
ASTON UNIVERSITY | £104,712 | £ 104,712 |
INNOVATE UK | ||
IG INNOVATIONS | £49,520 | £ 24,760 |
People |
ORCID iD |
Adrian Deverell (Project Manager) |